
Experts Issue Caution for Evolocumab Following New Review of FOURIER Data; Amgen Disputes the Claims
Investigators writing in BMJ Open called for “a complete restoration of FOURIER trial data.” Amgen, the maker of evolocumab, said it stood by the data.




























